Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of atogepant for preventive treatment of episodic migraine in pediatric participants aged 6 to 17 years
MOH_2023-05-28_012643Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atogepant in episodic migraine (6 arms), sponsored by AbbVie Inc. Started May 2023; status: recruiting.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on MOH_2023-05-28_012643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-28_012643.